Health Affairs December 9, 2025
Editor’s Note
This article is the latest in the Health Affairs Forefront featured topic, “Health Policy at a Crossroads,” produced with the support of the Commonwealth Fund and the Robert Wood Johnson Foundation. Articles in this topic offer timely analyses of regulatory, legislative, and judicial developments in health policy under the Trump-Vance administration and the 119th Congress. Health Affairs Forefront alone reviews all submissions then selects, edits, and publishes them only if they meet Forefront’s editorial standards.
In late November, the Centers for Medicare and Medicaid Services (CMS) announced the negotiated prices (Maximum Fair Prices or MFPs) for prescription drugs under the second cycle of the Medicare Drug Price Negotiation Program (MDPNP). By statute, these prices will become effective for...
Today's Sponsors
Today's Sponsor